Cargando…
Contemporary RNA Therapeutics for Glioblastoma
Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM....
Autores principales: | Melnick, Kaitlyn, Dastmalchi, Farhad, Mitchell, Duane, Rahman, Maryam, Sayour, Elias J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186014/ https://www.ncbi.nlm.nih.gov/pubmed/34101090 http://dx.doi.org/10.1007/s12017-021-08669-9 |
Ejemplares similares
-
The role of CMV in glioblastoma and implications for immunotherapeutic strategies
por: Rahman, Maryam, et al.
Publicado: (2018) -
Optimizing T Cell-Based Therapy for Glioblastoma
por: Karachi, Aida, et al.
Publicado: (2021) -
Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas
por: Grady, Clare, et al.
Publicado: (2022) -
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes
por: Sayour, Elias J., et al.
Publicado: (2018) -
COVD-02. ADAPTING RNA-NANOPARTICLE VACCINES FROM GLIOBLASTOMA TO SARS-COV-2
por: Mendez-Gomez, Hector, et al.
Publicado: (2020)